Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone45-0687-2262
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Acasti Pharma (NASDAQ:ACST) Frequently Asked Questions
What is Acasti Pharma's stock symbol?
Acasti Pharma trades on the NASDAQ under the ticker symbol "ACST."
How were Acasti Pharma's earnings last quarter?
Acasti Pharma Inc (NASDAQ:ACST) issued its earnings results on Wednesday, August, 14th. The biopharmaceutical company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01. View Acasti Pharma's Earnings History.
What price target have analysts set for ACST?
5 brokers have issued twelve-month target prices for Acasti Pharma's stock. Their forecasts range from $6.00 to $7.75. On average, they expect Acasti Pharma's share price to reach $6.9375 in the next twelve months. This suggests a possible upside of 228.8% from the stock's current price. View Analyst Price Targets for Acasti Pharma.
What is the consensus analysts' recommendation for Acasti Pharma?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Acasti Pharma.
What are Wall Street analysts saying about Acasti Pharma stock?
Here are some recent quotes from research analysts about Acasti Pharma stock:
- 1. According to Zacks Investment Research, "Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada. " (8/27/2019)
- 2. HC Wainwright analysts commented, "Our price target of $6/share is based on an equally weighted composite of: (a) $4.96/share, as a 25x multiple of taxed and diluted 2030 EPS of $1.23 discounted back to FY 2020 at 20%; and (b) an NPV discounted cash flow between FY 2020-2030 of $6.32/share, with a discount rate of 13% and growth rate of 2%. These assumptions are in-line with the expected PE multiple and discount rates of an early development-stage biopharmaceutical company." (8/15/2019)
Has Acasti Pharma been receiving favorable news coverage?
Press coverage about ACST stock has been trending somewhat negative on Monday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Acasti Pharma earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Acasti Pharma.
Who are some of Acasti Pharma's key competitors?
Some companies that are related to Acasti Pharma include Stoke Therapeutics (STOK), Vanda Pharmaceuticals (VNDA), Capstone Therapeutics (CAPS), Karyopharm Therapeutics (KPTI), Catalyst Pharmaceuticals (CPRX), Advanz Pharma (CXRXF), Rocket Pharmaceuticals (RCKT), OrganiGram (OGI), MacroGenics (MGNX), Vectura Group (VEGPF), Revance Therapeutics (RVNC), TG Therapeutics (TGTX), Synthorx (THOR), Aurinia Pharmaceuticals (AUPH) and DiaMedica Therapeutics (DMCAF).
What other stocks do shareholders of Acasti Pharma own?
Who are Acasti Pharma's key executives?
Acasti Pharma's management team includes the folowing people:
- Ms. Janelle D' Alvise, Pres, CEO & Director
- Dr. Pierre Lemieux, Co-Founder and Chief Operating & Scientific Officer
- Mr. Jean-François Boily, VP of Fin.
- Mr. Brian James Groch, Chief Commercial Officer (Age 52)
Who are Acasti Pharma's major shareholders?
Which major investors are buying Acasti Pharma stock?
How do I buy shares of Acasti Pharma?
Shares of ACST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Acasti Pharma's stock price today?
One share of ACST stock can currently be purchased for approximately $2.11.
How big of a company is Acasti Pharma?
Acasti Pharma has a market capitalization of $179.73 million. The biopharmaceutical company earns $-39,290,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis. View Additional Information About Acasti Pharma.
What is Acasti Pharma's official website?
How can I contact Acasti Pharma?
Acasti Pharma's mailing address is 545 Promenade du Centropolis Suite 100, Laval A8, H7T 0A3. The biopharmaceutical company can be reached via phone at 45-0687-2262 or via email at [email protected]
MarketBeat Community Rating for Acasti Pharma (NASDAQ ACST)
MarketBeat's community ratings are surveys of what our community members think about Acasti Pharma and other stocks. Vote "Outperform" if you believe ACST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACST will underperform the S&P 500 over the long term. You may vote once every thirty days.
